ADMET and DMPK

Scope & Guideline

Unlocking the potential of drug development with cutting-edge insights.

Introduction

Immerse yourself in the scholarly insights of ADMET and DMPK with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1848-7718
PublisherIAPC PUBLISHING
Support Open AccessYes
CountryCroatia
TypeJournal
Convergefrom 2013 to 2024
AbbreviationADMET DMPK / ADMET DMPK
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressS ALICA 4, ZAGREB HR-10000, CROATIA

Aims and Scopes

The journal 'ADMET and DMPK' focuses on the intersection of drug absorption, distribution, metabolism, excretion, and toxicity (ADMET) alongside drug metabolism and pharmacokinetics (DMPK). It serves as a platform for researchers to publish studies that contribute to the understanding of how drugs behave in biological systems, their efficacy, and safety profiles.
  1. ADMET Profiling:
    Research focusing on the absorption, distribution, metabolism, excretion, and toxicity of drugs, providing insights into their pharmacological behavior and safety.
  2. Drug Formulation and Delivery Systems:
    Studies on the development and optimization of drug delivery systems, including nanomaterials and liposomes, aimed at enhancing drug efficacy and bioavailability.
  3. Electrochemical Sensing and Biosensors:
    Innovative methodologies involving electrochemical sensors for detecting drug compounds and biomarkers, which are crucial for pharmacokinetic studies and therapeutic monitoring.
  4. Pharmacokinetics and Modeling:
    Research involving the modeling of drug pharmacokinetics, including novel approaches to predict drug behavior in vivo, which is essential for drug development.
  5. Nanotechnology in Drug Development:
    Exploration of nanotechnology applications in drug formulation, delivery, and diagnostics, highlighting the transformative potential of nanomaterials in enhancing therapeutic outcomes.
The journal 'ADMET and DMPK' has seen a rise in specific themes that reflect current trends in drug development and delivery. These emerging areas indicate the journal's adaptability to the evolving landscape of pharmaceutical research.
  1. Nanomaterials and Drug Delivery Innovations:
    There is an increasing focus on the application of nanomaterials for drug delivery, enhancing bioavailability, and overcoming biological barriers, which is crucial for developing effective therapies.
  2. Electrochemical Biosensors for Biomarker Detection:
    The trend towards using advanced electrochemical methods for detecting biomarkers and drugs highlights the importance of rapid and sensitive diagnostic tools in pharmacokinetics.
  3. Sustainable and Green Chemistry Approaches:
    Research emphasizing environmentally friendly synthesis methods for drug compounds and materials is gaining traction, reflecting a broader commitment to sustainability in pharmaceutical sciences.
  4. Advanced In Vitro Models for Drug Testing:
    The emergence of sophisticated in vitro models, including 3D cell cultures and organ-on-a-chip systems, underscores a shift towards more predictive and ethical approaches in drug testing.
  5. Personalized Medicine and Pharmacogenomics:
    An increasing interest in the interplay between genetics and drug response is evident, indicating a trend towards personalized medicine that tailors treatments based on individual genetic profiles.

Declining or Waning

While 'ADMET and DMPK' continues to advance in various areas, certain themes seem to be losing prominence in recent publications. This shift may reflect evolving research priorities or emerging technologies overshadowing older methodologies.
  1. Traditional Pharmaceutical Formulations:
    Research focusing on conventional drug formulation techniques is becoming less frequent as new technologies, particularly nanotechnology and advanced delivery systems, gain traction.
  2. Basic Pharmacological Studies:
    Studies that solely focus on basic pharmacological effects without integrating ADMET or DMPK perspectives are declining, as the journal emphasizes comprehensive approaches that include these critical factors.
  3. Animal Studies in Drug Development:
    There is a noticeable decrease in studies relying solely on animal models for drug testing, as the field moves towards more ethical and predictive in vitro models, including organ-on-a-chip technologies.

Similar Journals

XENOBIOTICA

Unveiling the Complexities of Xenobiotic Interactions.
Publisher: TAYLOR & FRANCIS LTDISSN: 0049-8254Frequency: 12 issues/year

XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.

PHARMACEUTICAL RESEARCH

Advancing pharmaceutical innovation through rigorous research.
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 0724-8741Frequency: 12 issues/year

PHARMACEUTICAL RESEARCH, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the ever-evolving field of pharmaceutical sciences. With an ISSN of 0724-8741 and an E-ISSN of 1573-904X, this journal has established itself as a critical hub for disseminating innovative research from 1984 to 2024. The journal holds impressive rankings in prominent categories, including Q2 in Biotechnology and Q2 in Pharmaceutical Science, reflecting its robust impact on the global scientific community. The journal aims to provide researchers, professionals, and students with high-quality articles that contribute significantly to the advancement of drug development and medicinal applications. Although it does not currently offer Open Access options, its rigorous peer-review process ensures that only the highest caliber research is published, making it a valuable resource for those seeking to stay at the forefront of pharmaceutical innovation.

TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH

Fostering breakthroughs in drug development and application.
Publisher: PHARMACOTHERAPY GROUPISSN: 1596-5996Frequency: 2 issues/year

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

BMC Pharmacology & Toxicology

Fostering collaboration in pharmacology and toxicology.
Publisher: BMCISSN: Frequency: 1 issue/year

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

JOURNAL OF PHARMACEUTICAL SCIENCES

Advancing pharmaceutical knowledge, shaping future innovations.
Publisher: ELSEVIER SCIENCE INCISSN: 0022-3549Frequency: 12 issues/year

The JOURNAL OF PHARMACEUTICAL SCIENCES, published by ELSEVIER SCIENCE INC, stands as a cornerstone in the field of pharmaceutical sciences, offering a platform for innovative research and advancements since its inception in 1961. With an impressive Scopus Rank of #36 out of 183 in the Pharmaceutical Science category, this journal is recognized for its commitment to disseminating high-quality, peer-reviewed studies that significantly contribute to the realms of pharmacology, toxicology, and pharmaceutics. Holding a 2023 Q2 category quartile, it attracts a diverse readership encompassing researchers, industry professionals, and students eager to advance their understanding and expertise. While the journal is not open access, it ensures valuable insights in every issue, making it an essential resource for those dedicated to the evolving landscape of pharmaceutical research. With an impact factor that reflects its relevance and influence, the JOURNAL OF PHARMACEUTICAL SCIENCES continues to shape the discourse in its domain, fostering innovation and collaboration among scholars worldwide.

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Empowering Insights in Assay Technologies and Therapeutics
Publisher: MARY ANN LIEBERT, INCISSN: 1540-658XFrequency: 8 issues/year

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Innovating Solutions for Modern Pharmaceutical Challenges
Publisher: TAYLOR & FRANCIS LTDISSN: 0363-9045Frequency: 12 issues/year

Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Connecting Basic Science with Clinical Applications
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Pharmaceutical Sciences

Exploring innovative solutions in pharmaceutical sciences.
Publisher: TABRIZ UNIV MEDICAL SCIENCES, FAC PHARMACYISSN: 1735-403XFrequency: 4 issues/year

Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.

Acta Pharmaceutica Sinica B

Pioneering Innovations in Drug Development
Publisher: INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCESISSN: 2211-3835Frequency: 6 issues/year

Acta Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.